Identification of Beta-Sitosterol and Stigmasterol as Possible Inhibitors of 5 Alpha-Reductase 1: An In-Silico Study

Pardis Zamani¹, Omid Mokhtari¹ and Fariba Dehghanian^{1,*}

¹Department of Cell and Molecular Biology & Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran

*Corresponding author: Department of Cell and Molecular Biology & Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran. Email: fa.dehghanian@sci.ui.ac.ir

Received 2021 December 02; Revised 2022 January 04; Accepted 2022 January 05.

Abstract

Background: Dihydrotestosterone (DHT), the most critical pathogenic androgen in hair loss, is identified as an etiologic factor of androgenetic alopecia (AGA). The AGA is a genetically common disorder among men and is characterized by the progressive conversion of hair follicles into small vellus hair. Steroid 5 alpha-reductase type 1 (5AR1) is a crucial target responsible for this gradual replacement. The 5AR1 function is determined by converting testosterone to DHT. The inhibitors of 5AR1 play their role by blocking the DHT production pathway.

Objectives: This study focused on the potent inhibitors of the 5AR1 enzyme to suggest effective synthetic drugs for restoring hair loss with fewer side effects.

Methods: The three-dimensional structure of 5AR1 was created using homology modeling methods. Then, the inhibitory effects of some significant compounds from natural sources were examined on the 5AR1 protein using molecular docking approaches.

Results: The obtained results suggest that two natural compounds isolated from *Serenoa repens*, including beta-sitosterol and stigmasterol, could inhibit the regular activity of 5AR1 and can be recommended as safe and novel AGA medicines for hair restoration.

Keywords: DHT, 5AR1, Homology Modeling, Molecular Docking

1. Background

Androgenetic alopecia (AGA), or male-pattern hair loss (MPHL), is the most common form of hair loss occurring in 80% of men aged 80 years or older (1). The AGA is an androgen-dependent disorder, and the miniaturization of scalp hair follicles results in decreased hair density, thin fibers, and severe forms that cause baldness (2, 3). Dihydrotestosterone (DHT) is the primary specific androgen hormone involved in AGA. In the DHT biosynthesis pathway, an integral membrane enzyme, 5 alpha-reductase (5AR), plays a regulatory role by reducing testosterone to DHT.

The 5AR family is related to androgen-dependent disorders and consists of two isozymes, 5 alpha-reductase type 1 (5AR1) and 5 alpha-reductase type 2 (5AR2) (4, 5). The 5AR1 and 5AR2 are nicotinamide adenine dinucleotide phosphate-dependent enzymes and share a low sequence identity of 47%. These two isozymes are encoded by *SRD5A1* and *SRD5A2* genes, located in different chromosomal locations. The 5AR1 is located on the 5p15.31 chromosome; however, 5AR2 is located on chromosome 2P23.1 in the human genome (6).

Moreover, the tissue expression patterns of 5AR1 and 5AR2 are different. Type 1 is expressed in nongenital skin, fetal scalp, and liver; nevertheless, type 2 is predominantly expressed in male genital tissues, prostate, and seminal vesicles. The 5AR2 is responsible for virilizing the external male genitalia during puberty, benign prostatic hyperplasia (BPH), and prostate adenocarcinoma tissues (7-9). Since it has been reported that DHT-related disorders include AGA, BPH, and prostate cancer, which can be treated by lowering DHT levels, 5AR is identified as an efficient drug target (10).

The 5AR inhibitors are applied in restoring hair loss and regenerating miniaturized hair. Hair restoration is defined by the change in terminal hair count and width. Nonsurgical hair restoration options ranging from drug therapy to laser treatments are cheaper and do not carry risks associated with surgical hairline restoration, including hair transplantation (11). In this regard, two potent synthetic drugs, including finasteride and dutasteride, have been established to inhibit 5AR1 and 5AR2. Finasteride, a synthetic azo-steroid, is a more potent 5AR2 inhibitor than 5AR1, and dutasteride, widely used as AGA or BPH drug, in-

hibits both 5AR1 and 5AR2 (12).

According to the research conducted on the above-mentioned two drugs, it has been detected that finasteride can reduce the DHT level in serum by 70%, and the dutasteride inhibition effect showed a reducing amount of DHT level up to 90% in serum (13). Although finasteride and dutasteride performed well as efficient 5AR1 inhibitors and have been approved by the United States Food and Drug Administration (FDA), there have been more concerns about these two drugs' long-lasting side effects occurring in therapy within the last few years. Recent research has shown that finasteride and dutasteride have several sexual adverse effects, including libido reduction, dysfunction of erectile, ejaculation disorders, and gynecomastia (14, 15). Due to the safety concerns of these drugs, the detection of new, safe, and more effective 5AR inhibitors has become a new medication approach in the drug industry. As it is evidenced that 5AR1 is primarily expressed in the scalp, the inhibition of 5AR1 is the primary approach for AGA medication (16).

2. Objectives

Multiple traditional herbals are suggested as potent drugs to prevent this enzyme from working normally. The current study provided a library of herbal components as natural inhibitors and evaluated 5AR1 through homology modeling and molecular docking techniques. The current study library includes *Cedrus* and the henna tree (*Lawsonia inermis*), widely used in home remedy medications as topical therapy on the scalp. In various studies, other compounds mentioned as effective 5AR1 inhibitors that suggested stimulating hair regrowth and strengthening hair follicles are saw palmetto (*Serenoa repens*) and green tea (*Camellia sinensis*). Another highly recommended compound is vitamin B₂, also known as riboflavin. Moreover, two approved drugs, finasteride, and dutasteride, were chosen as positive controls to be compared with the aforementioned natural compounds (17-21).

3. Materials and Methods

3.1. Molecular Modeling

Since no three-dimensional (3D) structure of 5AR1 is currently available in the Protein Data Bank, homology modeling was utilized to generate the structure of SRD5A. Modeling approaches are the most reliable methods of predicting the 3D structure of an unknown protein based on known homologous reference protein with high identity to the novel protein as a template. The FASTA format of the 5AR1 enzyme protein sequence was retrieved from

the UniProt database (UniProtKB) with the accession number P18405. Based on best sequence alignment, the 3D structure of the protein was modeled using I-TASSER online server. The model was validated using various tools, such as ERRAT (22) and PROCHECK (23), to generate the Ramachandran plot.

3.2. Dataset Collection

The data of this study contained several medicinal plants widely used in home remedy medications. The present study identified the main components of these selected herbs. Cedrol, Cedrene, and Thujopsene are detected in *Cedar (Cedrus)*. Cedarwood essential oil is used as a skincare agent and hair growth medication (24). 1,4-naphthoquinone and Lawsone are active compounds isolated from *Lawsonia inermis*, also known as the henna tree. Studies evaluated that *Lawsonia inermis* compounds can slow hair loss and help nourish the scalp (25). Epicatechin gallate (ECG) and Epigallocatechin gallate (EGCG) are extracted from *Camellia sinensis* leaves (26-28). Other compounds are β -sitosterol and stigmaterol isolated from *Serenoa repens*. It is a popular herbal remedy that boosts hair growth and helps maintain scalp health (29, 30). Riboflavin (vitamin B₂) is a known antioxidant present in various plants. Research showed that riboflavin deficiency is associated with hair loss (31). Finasteride and dutasteride, used orally as 5AR1 inhibitors, were selected as positive controls. Figure 1 depicts the two-dimensional (2D) structure of all compounds.

3.3. Protein and Herbal Compounds Preparation

AutoDock Vina tools 1.5.6 were used to prepare 5AR1 and all compounds. The modeled structure of 5AR1 was obtained from I-TASSER online server and imported to the AutoDock Vina tools program. All water molecules were merged, polar hydrogens were added, and Kollman charge (32) and AD4 atom type were assigned. All the above-mentioned 3D structures of compounds were retrieved from PubChem data bank. Then, nonpolar hydrogens were eliminated; finally, Gasteiger charge was assigned to calculate the partial charge of all inhibitors.

3.4. Docking Studies

A molecular docking experiment was employed to determine the binding modes of selected components with 5AR1 active site residues. This study used AutoDock Vina to perform docking procedures to predict all inhibitors' best configuration within 5AR1 protein. The grid box parameter values were adjusted with the size of 25*25*25 in specific coordinates of x, y, and z-axis (x = 64.899, y = 62.246, and z = 66.772) and the space value of 1 Å to confirm the

Figure 1. Chemical structure of 5 alpha-reductase type 1 inhibitors from natural sources

best binding affinity of the inhibitor-protein complex. The Lamarckian genetic algorithms (33) were selected to perform docking. The best confirmation with the lowest binding energy estimated by Autodock Vina was visualized with PyMOL (34) and LigPlot plus (35) to provide a 2D diagram of the compound's interaction against 5AR1.

4. Results

4.1. Constructed Model of 5AR1 and Validation

Figure 2A illustrates the constructed homology model of 5AR obtained from I-TASSER. PROCHECK and ERRAT were used to evaluate the model structure. ERRAT results showed an overall quality factor of 92.0319. The Ramachandran plot of the model in Figure 2B shows that 86.97% of

residues are in the most favored regions (red), 9.8% in additional allowed regions, 1.8% in generously allowed regions, and 1.8% in disallowed regions. These statistics indicated that the modeled structure was suitable for docking simulation.

4.2. Docking Studies and Visualization

AutoDock Vina results revealed the orientation and interaction of all natural compounds against 5AR1. The most active compounds of the present study data collection are listed in Table 1. In addition, the binding energy, H bonds, and hydrophobic interactions are also shown. The docking results demonstrated that two compounds, β -sitosterol, and stigmasterol from *Serenoa repens*, had the strongest docking affinity of -10.7 and -10.1 kcal/mol, respectively, compared to the rest of the collection. In the second place,

Figure 2. (A) Three-dimensional modeled structure of 5 alpha-reductase type 1 (5AR1) enzyme using I-TASSER online server; (B) Ramachandran plot of 5AR1 model built via PROCHECK

ECG and EGCG isolated from *Camellia sinensis* leaves had the binding energy values of -9.9 and -9.6 kcal/mol, respectively. Riboflavin also showed high affinity (-9.1 kcal/mol) but weaker than the last two groups and equal to or greater than finasteride and dutasteride. *Cedrus*'s three main compounds (ie, Cedrol, Cedrene, and Thujopsene) displayed well but were weaker than the positive controls with the binding energy of -8.2, -8.3, and -7.9 kcal/mol, respectively. Lawsone and 1,4-naphthoquinone isolated from *Lawsonia inermis* exhibited the weakest affinity among other compounds with the active site residues of 5AR1. Screening the interaction details of the 5AR1-inhibitor complex from Lig-Plot+ showed that almost every compound interacts with Ser36, Tyr38, Trp56, Glu60, Tyr95, Ala116, Met119, Ala120, Phe123, Phe224, and Phe228. It could be inferred that these residues are critical in the binding site and can be considered important residues for inhibitors to bind within the active pocket of 5AR1. The most vital interaction regions of 5AR1 are shown in brown parts in Figure 3A. The 5AR1 residues involved in the interaction with stigmasterol and β -sitosterol are represented in 3D and 2D structures in Figures 3B-3C and 4A-4B, respectively.

5. Discussion

This study investigated the possible interactions between herbal inhibitors and 5AR1 protein using bioinformatics tools for AGA medication. Previously, Lin et al. worked on 5AR1 inhibitors to treat BPH; however, contrary

to the present work, they used AutoDock for the docking procedure (36). In comparison to AutoDock 4, AutoDock Vina significantly increases the average accuracy of the binding mode predictions and is incredibly faster. It has always been among the six first choices for docking analysis globally. In the present study, this software could define the interactions properly.

The current study findings revealed that all inhibitors have possible interactions with 5AR1. Moreover, among the selected inhibitors, the highest binding (-10.7 kcal/mol) belongs to stigmasterol. The present analyses indicated that stigmasterol binds to 5AR1 through only hydrophobic forces, and 13 amino acid residues were detected in the interaction site (Figure 3B). Therefore, it can be concluded that stigmasterol might be the best inhibitor. This inhibitor is suggested as the new choice for further investigations in this field. In the second rank, β -sitosterol was placed, with -10.1 kcal/mol. In the interaction site of β -sitosterol, 13 amino acid residues were detected (Figure 3C). The high energy value of this inhibitor showed the possible potential of this component to inhibit 5AR1.

Similar to the present study results, previous studies confirmed the possible ability of stigmasterol and β -sitosterol to inhibit 5AR. Prager et al. established the effectiveness of β -sitosterol to control AGA. For the first time, Prager et al. used a placebo-controlled double-blind method to examine the benefit of this botanical substance (37). In addition, Cabeza et al. reported the effect of β -sitosterol to inhibit 5AR1 in the hamster prostate (38). They

Table 1. List of Most Active Compounds

Compounds	Binding Energy (kcal/mol)	H-bond	Hydrophobic Interaction
Stigmasterol	-10.7	-	Ser36, Val37, Tyr38, Trp56, Gln59, Glu60, Tyr95, Ala116, Met119, Ala120, Glu202, Phe224, and Phe228
Beta-sitosterol	-10.1	Tyr95 and Glu202	Arg30, Ser36, Tyr38, His46, Glu60, Leu115, Ala116, Met119, Ala120, Phe224, and Phe228
Epigallactocatechin gallate	-9.9	Tyr56, Arg176, Tyr183, Arg232, and Tyr240	Tyr38, Gly39, Ala52, Tyr102, Met106, Gly108, Gly109, Met112, Leu172, Tyr199, and His236
Epicatechin gallate	-9.4	Arg98, Asn165, Asp169, and Asn198	Tyr38, Trp56, Glu60, Met119, Ala120, Phe123, Glu202, Phe221, Phe224, Phe228, and Leu229
Riboflavin	-9.1	Arg98 and Glu202	Tyr38, Trp56, Gln59, Glu60, Tyr95, Ala116, Met119, Ala120, Phe123, Phe224, Phe228, and Leu229
Dutasteride	-9.1	Arg30, Asn31, and Glu60	Ser36, Val37, Tyr38, His46, Gln59, Trp56, Leu115, Ala116, Met119, Ala120, Phe224, and Phe228
Finasteride	-8.5	Tyr95 and Arg98	Arg30, Ser36, Val37, Glu60, Ala116, Met119, Ala120, Phe123, Phe224, and Phe228
Cedrene	-8.3	-	Trp56, Gln59, Glu60, Tyr95, Ala120, Phe123, Glu202, Phe221, Phe224, Thr225, and Phe228
Cedrol	-8.2	Glu60	Gln59, Tyr95, Ala120, Phe123, Phe221, Phe224, and Phe228
Thujopsene	-7.9	-	Glu60, Tyr95, Met119, Ala120, Phe123, Phe221, Phe224, Thr225, and Phe228
Lawson	-7.4	Arg30 and Ser36	Val27, Tyr38, Ala116, Met119, Ala120, Phe224, and Phe228
1,4-naphthoquinone	-7.1	Arg30 and Ser36	Tyr38, Ala116, Met119, Ala120, Phe224, and Phe228

Figure 3. Most Critical interaction sites (brown regions) of 5 alpha-reductase type 1 (5AR1) protein (A); Active site residues of 5AR1 binding within stigmasterol (B) and beta-sitosterol (C)

showed β -sitosterol could decrease the prostate weight, and this effect was not related to the binding of β -sitosterol to the androgen receptor but the inhibition of 5AR. However, both targets were present in the prostate.

Furthermore, Upadhyay et al. investigated the effect of β -sitosterol phyto-vesicles to treat AGA. The aforementioned study confirmed the ability of β -sitosterol in the control of alopecia, and phyto-vesicles could increase this compound's water and lipid solubility (39). Finally, Chen et al. showed the potential of stigmasterol and β -sitosterol to target 5AR and inflammatory pathways, which confirmed

the efficacy of these components to treat AGA and BPH. In Chen et al.'s study, in vitro assays were used. The results of the aforementioned study determined the down-regulation of messenger ribonucleic acid expression profile characteristics of both disease processes in AGA (hair follicle dermal papilla cells) and BPH (LNCaP prostate cells) cell lines treated with stigmasterol or β -sitosterol. The aforementioned study proved that stigmasterol and β -sitosterol targeting 5AR and inflammatory mediators might represent a rational approach in treating AGA and BPH (40). Currently, available drugs for AGA are finasteride

Figure 4. Two-dimensional diagram of most potent inhibitors, namely stigmasterol (A) and beta-sitosterol (B), interactions within 5 alpha-reductase type 1

and dutasteride, which are synthetic. However, these two FDA-approved drugs have good inhibitory activity. Recent studies have shown that they can lead to severe adverse effects, including ejaculation dysfunction, reduction of libido, gynecomastia, and erectile disorder (41).

Docking analysis showed that dutasteride had a stronger binding affinity (-9.1 kcal/mol) than finasteride. In both inhibitors' interaction sites, H-bonds and hydrophobic forces get involved. In line with the present study results, some previous studies showed the inhibitory activity of these inhibitors. Rabasseda et al. and Olsen et al. indicated that dutasteride increased scalp hair growth in men with MPHL and suggested that type 1 and type 2 5AR might be important in the pathogenesis and treatment of MPHL (42, 43). In addition, Gubelin Harcha et al. determined that dutasteride increased hair growth and restoration in men with AGA. Gubelin Harcha et al. showed that dutasteride 0.5 mg could remarkably increase hair width and hair terminal count more than finasteride 1 mg, suggesting that dutasteride is more effective than finasteride in hair loss restoration (44). Eun et al. cited in Dhurat and Shanshanwal showed the potential of dutasteride to inhibit 5AR (type 1 and type 2), converting testosterone to DHT (45). Moreover, Inadomi et al., Shapiro et al., and Yanagisawa et al. conducted different pilot studies, and their results showed that finasteride is effective in the treatment of AGA patients (46-48). Finally, Arif et al. and Jung et al. introduced dutasteride as a treatment of choice for AGA (49, 50).

Liao et al. showed that EGCG and ECG extracted from

green tea could inhibit 5AR in the sex gland in the rat. Furthermore, Hiipakka et al. determined that EGCG can affect 5AR in cell-free but not whole-cell assays. They suggested that EGCG with long-chain fatty acids is active in both cell-free and whole-cell assay systems (26, 51). Koseki et al. suggested the potential of ECG to inhibit 5AR, which results in inhibiting the androgen-related pathogenesis of acne, testosterone conversion, and sebum synthesis. Therefore, it was proposed that it can be a helpful agent in the therapeutic strategy of acne (52). The present study confirmed the possible interactions between EGCG and ECG with 5AR by computational methods, similar to the aforementioned studies. Both inhibitors' energy values were about -9 kcal/mol.

The docking results of the present study estimated the strong interaction with -9 kcal/mol binding energy. Moreover, Nakayama et al. introduced riboflavin as a 5AR inhibitor. It was confirmed by Cho et al. that riboflavin has stronger potent inhibitory activity than other compounds, such as emodin and alizarin (53, 54). Although the binding energy of Cedrol (-8 kcal/mol) is not close to the highest ones, it was predicted to be a strong inhibitor. Zhang et al. showed the beneficial effect of Cedrol on hair loss and confirmed that it has a strong hair growth promotion effect (55). In addition, Deng et al. suggested that Cedrol nanoemulsion significantly improved pharmacokinetic properties and hair growth (56).

1,4-naphthoquinone was extracted from a natural source for the first time by Ishiguro et al. that showed the significant testosterone 5AR inhibitory activity (57). Al-

though Ishiguro et al. examined the inhibitory activity of 1,4-naphthoquinone, the current study findings showed that it has the lowest binding energy (-7.1 kcal/mol), compared to other inhibitors. Therefore, it can be concluded that this inhibitor has the weakest interaction with 5AR1. Although Lawsone, Thujopsene, and Cedrene were listed as 5AR1 inhibitors in some reviews, any experimental studies related to these components were detected. By considering the docking results of the present study, it can be concluded that among these inhibitors, Cedrene is more capable of inhibiting 5AR1 due to the highest binding affinity (-8.3 kcal/mol), compared to Thujopsene and Lawsone with binding energy values of -7.9 and -7.4 kcal/mol, respectively.

Docking analysis showed that some regions were critical in the interaction between selected inhibitors and 5AR1, shown in Figure 3A as brown regions. Among amino acid residues involved in all interactions, 11 amino acids (ie, Ser36, Tyr38, Trp56, Glu60, Tyr95, Ala116, Met119, Ala120, Phe123, Phe224, and Phe228) were detected in the majority of inhibitors and 5AR1 interaction sites. Therefore, it can be suggested that the aforementioned residues are essential to inhibit this protein and might be helpful in designing new targets for the next generation of 5AR1 inhibitors.

5.1. Conclusions

The present study aimed to examine the potential activity of herbal components as 5AR1 inhibitors using in-silico analysis, which can be helpful for AGA treatments and restoration of hair follicles. In conclusion, the present predictions determined two inhibitors (ie, β -sitosterol and stigmasterol) with the most robust interactions as the suggested compounds to be used in further investigations as the next generation of drugs to control AGA.

Footnotes

Authors' Contribution: Pardis Zamani and Omid Mokhtari performed in-silico analyses and wrote the manuscript. Fariba Dehghanian helped in editing the manuscript.

Conflict of Interests: The authors declare that they have no conflict of interest.

Funding/Support: This study was performed at the University of Isfahan, Iran, and supported by the Graduate Studies Office at this university.

References

- Shouche S, Yadav R, Saini P. In silico study of 5-alpha-reductase (5-AR) active site prediction and interaction with supernatural compound II. *Essence J*. 2020.
- Rathnayake D, Sinclair R. Male androgenetic alopecia. *Expert Opin Pharmacother*. 2010;**11**(8):1295-304. doi: [10.1517/14656561003752730](#). [PubMed: [20426708](#)].
- Yim E, Nole KL, Tosti A. 5alpha-Reductase inhibitors in androgenetic alopecia. *Curr Opin Endocrinol Diabetes Obes*. 2014;**21**(6):493-8. doi: [10.1097/MED.0000000000000112](#). [PubMed: [25268732](#)].
- Dhurat R, Sharma A, Rudnicka L, Kroumpouzos G, Kassir M, Galadari H, et al. 5-Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety. *Dermatol Ther*. 2020;**33**(3). doi: [10.1016/j.dth.13379](#).
- Occhiato EG, Guarna A, Danza G, Serio M. Selective non-steroidal inhibitors of 5 alpha-reductase type 1. *J Steroid Biochem Mol Biol*. 2004;**88**(1):1-16. doi: [10.1016/j.jsbmb.2003.10.004](#). [PubMed: [15026079](#)].
- Huhtaniemi I. Dedication. *Encyclopedia of Endocrine Diseases*. Academic Press; 2019. doi: [10.1016/b978-0-12-812199-3.09008-3](#).
- Avendano A, Paradisi I, Cammarata-Scalisi F, Callea M. 5-alpha-Reductase type 2 deficiency: is there a genotype-phenotype correlation? A review. *Hormones (Athens)*. 2018;**17**(2):197-204. doi: [10.1007/s42000-018-0013-9](#). [PubMed: [29858846](#)].
- Marks LS. 5 α -reductase: history and clinical importance. *Rev Urol*. 2004;**6**(Suppl 9):S11.
- Thigpen AE, Silver RI, Guileyardo JM, Casey ML, McConnell JD, Russell DW. Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. *J Clin Invest*. 1993;**92**(2):903-10. doi: [10.1172/JCI116665](#). [PubMed: [7688765](#)]. [PubMed Central: [PMC294929](#)].
- Metcalf BW, Levy MA, Holt DA. Inhibitors of steroid 5 α -reductase in benign prostatic hyperplasia, male pattern baldness and acne. *Trends Pharmacol Sci*. 1989;**10**(12):491-5. doi: [10.1016/0165-6147\(89\)90048-5](#).
- Tsunemi Y, Irisawa R, Yoshiie H, Brotherton B, Ito H, Tsuboi R, et al. Long-term safety and efficacy of dutasteride in the treatment of male patients with androgenetic alopecia. *J Dermatol*. 2016;**43**(9):1051-8. doi: [10.1016/j.jid.2016.08.013](#). [PubMed: [26893187](#)].
- Carson C, Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. *Urology*. 2003;**61**(4):2-7. doi: [10.1016/s0090-4295\(03\)00045-1](#).
- Kiguradze T, Temps WH, Yarnold PR, Cashy J, Brannigan RE, Nardone B, et al. Persistent erectile dysfunction in men exposed to the 5alpha-reductase inhibitors, finasteride, or dutasteride. *PeerJ*. 2017;**5**:e3020. doi: [10.7717/peerj.3020](#). [PubMed: [28289563](#)]. [PubMed Central: [PMC5346286](#)].
- Fertig RM, Gamret AC, Darwin E, Gaudi S. Sexual side effects of 5-alpha-reductase inhibitors finasteride and dutasteride: A comprehensive review. *Dermatol Online J*. 2017;**23**(11). [PubMed: [29447628](#)].
- Marihart S, Harik M, Djavan B. Dutasteride: a review of current data on a novel dual inhibitor of 5 α reductase. *Reviews in urology*. 2005;**7**(4):203.
- Bayne EK, Flanagan J, Einstein M, Ayala J, Chang B, Azzolina B, et al. Immunohistochemical localization of types 1 and 2 5alpha-reductase in human scalp. *Br J Dermatol*. 1999;**141**(3):481-91. doi: [10.1046/j.1365-2133.1999.03042.x](#). [PubMed: [10583052](#)].
- Goldsmith GA. Riboflavin Deficiency. *Riboflavin*. Springer; 1975. p. 221-44. doi: [10.1007/978-1-4613-4419-3_7](#).
- Jain VC, Shah DP, Sonani NG, Dhakara S, Patel NM. Pharmacognostical and preliminary phytochemical investigation of Lawsonia inermis L. leaf. *Romanian J Biol-Plant Biol*. 2010;**55**:127-33.
- Kalwat JI. The Use of Serenoa Repens (Saw Palmetto) in Hair Care Products. *Biomed J Sci Tech Res*. 2019;**13**(1). doi: [10.26717/bjstr.2019.13.002348](#).
- Natarajan SB, Chandran SP, Khan SH, Natarajan P, Rengarajan K. Versatile Health Benefits of Catechin from Green Tea (Camellia sinensis). *Curr Nutr Food Sci*. 2019;**15**(1):3-10. doi: [10.2174/1573401313666171003150503](#).
- Saini P. 10 Best Essential Oils for Hair Growth. *Skin*. 2018.
- Colovos C, Yeates TO. Verification of protein structures: patterns of nonbonded atomic interactions. *Protein Sci*. 1993;**2**(9):1511-9. doi: [10.1002/pro.5560020916](#). [PubMed: [8401235](#)]. [PubMed Central: [PMC2142462](#)].

23. Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK: a program to check the stereochemical quality of protein structures. *J Appl Crystallogr*. 1993;**26**(2):283–91. doi: [10.1107/s002188982009944](https://doi.org/10.1107/s002188982009944).
24. Chaudhary A, Kaur P, Singh B, Pathania V. Chemical Composition of Hydrodistilled and Solvent Volatiles Extracted from Woodchips of Himalayan Cedrus: *Cedrus deodara* (Roxb.) Loud. *Nat Prod Commun*. 2009;**4**(9). doi: [10.1177/1934578x0900400920](https://doi.org/10.1177/1934578x0900400920).
25. Rathi V, Rathi J, Tamizharasi S, Pathak A. Plants used for hair growth promotion: A review. *Pharmacogn Rev*. 2008;**2**(3):185–7.
26. Hiipakka RA, Zhang H, Dai W, Dai Q, Liao S. Structure–activity relationships for inhibition of human 5 α -reductases by polyphenols. *Biochem Pharmacol*. 2002;**63**(6):1165–76. doi: [10.1016/s0006-2952\(02\)00848-1](https://doi.org/10.1016/s0006-2952(02)00848-1).
27. Kwon OS, Han JH, Yoo HG, Chung JH, Cho KH, Eun HC, et al. Human hair growth enhancement in vitro by green tea epigallocatechin-3-gallate (EGCG). *Phytomedicine*. 2007;**14**(7-8):551–5. doi: [10.1016/j.phymed.2006.09.009](https://doi.org/10.1016/j.phymed.2006.09.009). [PubMed: [17092697](https://pubmed.ncbi.nlm.nih.gov/17092697/)].
28. Zgonc Skulj A, Poljsak N, Kocevar Glavac N, Kreft S. Herbal preparations for the treatment of hair loss. *Arch Dermatol Res*. 2020;**312**(6):395–406. doi: [10.1007/s00403-019-02003-x](https://doi.org/10.1007/s00403-019-02003-x). [PubMed: [31680216](https://pubmed.ncbi.nlm.nih.gov/31680216/)].
29. Dhariwala MY, Ravikumar P. An overview of herbal alternatives in androgenetic alopecia. *J Cosmet Dermatol*. 2019;**18**(4):966–75. doi: [10.1111/jocd.12930](https://doi.org/10.1111/jocd.12930). [PubMed: [30980598](https://pubmed.ncbi.nlm.nih.gov/30980598/)].
30. Rossi A, Mari E, Scarno M, Garelli V, Maxia C, Scali E, et al. Comparative effectiveness of finasteride vs Serenoa repens in male androgenetic alopecia: A two-year study. *Int J Immunopathol Pharmacol*. 2012;**25**(4):1167–73. doi: [10.1177/039463201202500435](https://doi.org/10.1177/039463201202500435). [PubMed: [23298508](https://pubmed.ncbi.nlm.nih.gov/23298508/)].
31. Almohanna HM, Ahmed AA, Tsatalis JP, Tosti A. The Role of Vitamins and Minerals in Hair Loss: A Review. *Dermatol Ther (Heidelb)*. 2019;**9**(1):51–70. doi: [10.1007/s13555-018-0278-6](https://doi.org/10.1007/s13555-018-0278-6). [PubMed: [30547302](https://pubmed.ncbi.nlm.nih.gov/30547302/)]. [PubMed Central: [PMC6380979](https://pubmed.ncbi.nlm.nih.gov/PMC6380979/)].
32. Wang J, Wang W, Kollman PA, Case DA. Automatic atom type and bond type perception in molecular mechanical calculations. *J Mol Graph Model*. 2006;**25**(2):247–60. doi: [10.1016/j.jmgm.2005.12.005](https://doi.org/10.1016/j.jmgm.2005.12.005). [PubMed: [16458552](https://pubmed.ncbi.nlm.nih.gov/16458552/)].
33. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. *J Comput Chem*. 1998;**19**(14):1639–62. doi: [10.1002/\(sici\)1096-987x\(19981115\)19:14<1639::Aid-jcc10>3.0.Co;2-b](https://doi.org/10.1002/(sici)1096-987x(19981115)19:14<1639::Aid-jcc10>3.0.Co;2-b).
34. DeLano WL. Pymol: An open-source molecular graphics tool. **40**. CCP4; 2002. p. 82–92.
35. Laskowski RA, Swindells MB. LigPlot+: Multiple ligand-protein interaction diagrams for drug discovery. *J Chem Inf Model*. 2011;**51**(10):2778–86. doi: [10.1021/ci200227u](https://doi.org/10.1021/ci200227u). [PubMed: [21919503](https://pubmed.ncbi.nlm.nih.gov/21919503/)].
36. Lin Q, Lin D, Zhang Y. In silico model and design of novel 5 α -reductase inhibitors for treatment of benign prostatic hyperplasia. *Trop J Pharm Res*. 2021;**18**(10). doi: [10.4314/tjpr.v18i10.12](https://doi.org/10.4314/tjpr.v18i10.12).
37. Prager N, Bickett K, French N, Marcovici G. A randomized, double-blind, placebo-controlled trial to determine the effectiveness of botanically derived inhibitors of 5 α -reductase in the treatment of androgenetic alopecia. *J Altern Complement Med*. 2002;**8**(2):143–52.
38. Cabeza M, Bratoef E, Heuze I, Ramírez E, Sánchez M, Flores E. Effect of beta-sitosterol as inhibitor of 5 α -reductase in hamster prostate. Proceedings-Western Pharmacology Society; 2003. p. 153–5.
39. Upadhyay K, Gupta NK, Dixit VK. Development and characterization of phyto-vesicles of beta-sitosterol for the treatment of androgenetic alopecia. *Arch Dermatol Res*. 2012;**304**(7):511–9. doi: [10.1007/s00403-011-1199-8](https://doi.org/10.1007/s00403-011-1199-8). [PubMed: [22160579](https://pubmed.ncbi.nlm.nih.gov/22160579/)].
40. Chen L, Wang J, Mouser G, Li YC, Marcovici G. Blockade of Androgen Markers Using a Novel Betasitosterol, Thioctic Acid and Carnitine-containing Compound in Prostate and Hair Follicle Cell-based Assays. *Phytother Res*. 2016;**30**(6):1016–20. doi: [10.1002/ptr.5611](https://doi.org/10.1002/ptr.5611). [PubMed: [26990224](https://pubmed.ncbi.nlm.nih.gov/26990224/)].
41. Hirshburg JM, Kelsey PA, Therrien CA, Gavino AC, Reichenberg JS. Adverse effects and safety of 5-alpha reductase inhibitors (finasteride, dutasteride): A systematic review. *J Clin Aesthet Dermatol*. 2016;**9**(7):56–62.
42. Olsen EA, Hordinsky M, Whiting D, Stough D, Hobbs S, Ellis ML, et al. The importance of dual 5 α -reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. *J Am Acad Dermatol*. 2006;**55**(6):1014–23. doi: [10.1016/j.jaad.2006.05.007](https://doi.org/10.1016/j.jaad.2006.05.007). [PubMed: [17110217](https://pubmed.ncbi.nlm.nih.gov/17110217/)].
43. Rabasseda X. Dutasteride: a potent dual inhibitor of 5-alpha-reductase for benign prostatic hyperplasia. *Drugs Today (Barc)*. 2004;**40**(8):649–61. doi: [10.1358/dot.2004.40.8.850468](https://doi.org/10.1358/dot.2004.40.8.850468). [PubMed: [15510237](https://pubmed.ncbi.nlm.nih.gov/15510237/)].
44. Gubelin Harcha W, Barboza Martinez J, Tsai TF, Katsuoka K, Kawashima M, Tsuboi R, et al. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. *J Am Acad Dermatol*. 2014;**70**(3):489–498 e3. doi: [10.1016/j.jaad.2013.10.049](https://doi.org/10.1016/j.jaad.2013.10.049). [PubMed: [24411083](https://pubmed.ncbi.nlm.nih.gov/24411083/)].
45. Dhurat R, Shanshanwal S. Randomized controlled evaluator blinded study of dutasteride versus finasteride in men with androgenetic alopecia. *J Am Acad Dermatol*. 2016;**74**(5, Supplement 1). doi: [10.1016/j.jaad.2016.02.542](https://doi.org/10.1016/j.jaad.2016.02.542).
46. Inadomi T. Efficacy of Finasteride for Treating Patients with Androgenetic Alopecia who are Pileous in other Areas: A Pilot Study in Japan. *Indian J Dermatol*. 2014;**59**(2):163–5. doi: [10.4103/0019-5154.127677](https://doi.org/10.4103/0019-5154.127677). [PubMed: [24700935](https://pubmed.ncbi.nlm.nih.gov/24700935/)]. [PubMed Central: [PMC3969676](https://pubmed.ncbi.nlm.nih.gov/PMC3969676/)].
47. Shapiro J, Kaufman KD. Use of finasteride in the treatment of men with androgenetic alopecia (male pattern hair loss). *J Invest Dermatol Symp Proc*. 2003;**8**(1):20–3. doi: [10.1046/j.1523-1747.2003.12167.x](https://doi.org/10.1046/j.1523-1747.2003.12167.x). [PubMed: [12894990](https://pubmed.ncbi.nlm.nih.gov/12894990/)].
48. Yanagisawa M, Fujimaki H, Takeda A, Nemoto M, Sugimoto T, Sato A. Long-term (10-year) efficacy of finasteride in 523 Japanese men with androgenetic alopecia. *Clin Res Trials*. 2019;**5**(5). doi: [10.15761/crt.1000273](https://doi.org/10.15761/crt.1000273).
49. Arif T, Dorjay K, Adil M, Sami M. Dutasteride in Androgenetic Alopecia: An Update. *Curr Clin Pharmacol*. 2017;**12**(1):31–5. doi: [10.2174/1574884712666170310111125](https://doi.org/10.2174/1574884712666170310111125). [PubMed: [28294070](https://pubmed.ncbi.nlm.nih.gov/28294070/)].
50. Jung JY, Yeon JH, Choi JW, Kwon SH, Kim BJ, Youn SW, et al. Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride. *Int J Dermatol*. 2014;**53**(11):1351–7. doi: [10.1111/ijd.12060](https://doi.org/10.1111/ijd.12060). [PubMed: [24898559](https://pubmed.ncbi.nlm.nih.gov/24898559/)].
51. Liao S, Hiipakka RA. Selective inhibition of steroid 5 alpha-reductase isozymes by tea epicatechin-3-gallate and epigallocatechin-3-gallate. *Biochem Biophys Res Commun*. 1995;**214**(3):833–8. doi: [10.1006/bbrc.1995.2362](https://doi.org/10.1006/bbrc.1995.2362). [PubMed: [7575552](https://pubmed.ncbi.nlm.nih.gov/7575552/)].
52. Koseki J, Matsumoto T, Matsubara Y, Tsuchiya K, Mizuhara Y, Sekiguchi K, et al. Inhibition of Rat 5 α -Reductase Activity and Testosterone-Induced Sebum Synthesis in Hamster Sebocytes by an Extract of *Quercus acutissima* Cortex. *Evid Based Complement Alternat Med*. 2015;**2015**:853846. doi: [10.1155/2015/853846](https://doi.org/10.1155/2015/853846). [PubMed: [25709710](https://pubmed.ncbi.nlm.nih.gov/25709710/)]. [PubMed Central: [PMC4325551](https://pubmed.ncbi.nlm.nih.gov/PMC4325551/)].
53. Cho C, Bae J, Kim Y. 5 α -Reductase Inhibitory Components as Antiandrogens From Herbal Medicine. *J Acupunct Meridian Stud*. 2010;**3**(2):116–8. doi: [10.1016/s2005-2901\(10\)60021-0](https://doi.org/10.1016/s2005-2901(10)60021-0).
54. Nakayama O, Yagi M, Kiyoto S, Okuhara M, Kohsaka M. Riboflavin, a testosterone 5 alpha-reductase inhibitor. *J Antibiot (Tokyo)*. 1990;**43**(12):1615–6. doi: [10.7164/antibiotics.43.1615](https://doi.org/10.7164/antibiotics.43.1615). [PubMed: [2276981](https://pubmed.ncbi.nlm.nih.gov/2276981/)].
55. Zhang Y, Wang J, Qu F, Zhang Y, Su G, Zhao Y. Hair growth promotion effect of cedrol cream and its dermatopharmacokinetics. *RSC Advances*. 2018;**8**(73):42170. doi: [10.1039/c8ra08667b](https://doi.org/10.1039/c8ra08667b).
56. Deng Y, Huang F, Wang J, Zhang Y, Zhang Y, Su G, et al. Hair Growth Promoting Activity of Cedrol Nanoemulsion in C57BL/6 Mice and Its Bioavailability. *Molecules*. 2021;**26**(6). doi:

- [10.3390/molecules26061795](https://doi.org/10.3390/molecules26061795). [PubMed: [33806773](https://pubmed.ncbi.nlm.nih.gov/33806773/)]. [PubMed Central: [PMC8004917](https://pubmed.ncbi.nlm.nih.gov/PMC8004917/)].
57. Ishiguro K, Oku H, Kato T. Testosterone 5 α -reductase inhibitor bisnaphthoquinone derivative from *Impatiens balsamina*. *Phytother Res.* 2000;**14**(1):54–6. doi: [10.1002/\(sici\)1099-1573\(200002\)14:1<54::Aid-ptt540>3.0.Co;2-q](https://doi.org/10.1002/(sici)1099-1573(200002)14:1<54::Aid-ptt540>3.0.Co;2-q).